PHERGain and PHERGain-2 Studies Highlight Chemotherapy-Free Treatment for Early HER2-Positive Breast Cancer
The PHERGain and PHERGain-2 studies, presented at the ESMO Breast 2026 scientific congress, have demonstrated promising results in the treatment of early HER2-positive breast cancer. These studies focus on therapeutic de-escalation strategies that allow certain patients to avoid chemotherapy while maintaining high disease-free survival rates. The PHERGain study, involving 356 patients across Europe, showed that nearly 30% of patients could be treated without chemotherapy, achieving a five-year disease-free survival rate close to 90%. The PHERGain-2 trial, which included 396 patients, reported a 60% pathological complete response rate without initial chemotherapy. These findings suggest that targeted therapies, such as trastuzumab and pertuzumab, can effectively manage the disease while reducing treatment-related toxicity. 
